Investasi
Fitur
BiayaKeamanan
Akademi
Lainnya
Pluang+

Bandingkan Harga & Kinerja Citra Putra Realty Tbk. (CLAY) vs UBC Medical Indonesia Tbk. (LABS)

Citra Putra Realty Tbk.Trading
UBC Medical Indonesia Tbk.Trading

Kinerja harga (24 Jam Terakhir)

Statistik utama

Perbedaan Citra Putra Realty Tbk. dan UBC Medical Indonesia Tbk.: Citra Putra Realty Tbk. diperdagangkan di Rp2.810 (kapitalisasi pasar 7,12 T, volume 24 jam 10,7 rb), sedangkan UBC Medical Indonesia Tbk. diperdagangkan di Rp161 (kapitalisasi pasar 635,95 M, volume 24 jam 288,1 rb). Perbedaan utamanya: Citra Putra Realty Tbk. jauh lebih besar — sekitar 11,2× kapitalisasi pasar UBC Medical Indonesia Tbk., dan UBC Medical Indonesia Tbk. lebih aktif diperdagangkan (288,1 rb vs 10,7 rb). Mana yang lebih baik tergantung tujuan investasimu.

CLAYLABS
Kapitalisasi Pasar
7,12 T635,95 M
Volume
10,7 rb288,1 rb
Lot
1072,88 rb
Perputaran
30,11 jt46,81 jt
Harga Rata-rata
2.814,11162,49
Nilai Transaksi
30,11 jt46,81 jt
Harga Ekuilibrium Indikatif
163
Volume Ekuilibrium Indikatif
16

Perbandingan imbal hasil

Imbal hasil berjalan pada periode standar

Berita terkini

Berita terbaru kedua aset

CLAY
Lihat detail
LABS
Lihat detail

Tentang Citra Putra Realty Tbk.

PT Citra Putra Realty Tbk (“The Entity”) was established based on Notarial Deed of Herlina Pakpahan, S.H., No. 09 dated December 16, 2009. The majority shareholders (parent entity) of the Entity are PT Citra Putra Mandiri or better known as the OSO Group.

Selengkapnya di halaman CLAY

Tentang UBC Medical Indonesia Tbk.

PT UBC Medical Indonesia (the Company) was established under the framework of Law of the Republic of Indonesia No. 20 year 1994 concerning the Foreign Capital Investment, as amended by Law No. 25 year 2007 concerning the Capital Investment based on Notarial Deed No. 01 dated 4 June 2014 of Novita Puspitarini, S.H., Notary in Jakarta. The Company started its commercial activities in October 2014. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.

Selengkapnya di halaman LABS